enGene Names Amy Pott as Chief Global Commercialization Officer
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or 'enGene' or the 'Company'), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper.
This appointment marks a significant milestone, as the Company expects to file a Biologics License Application (BLA) with the FDA in mid-2026 for detalimogene voraplasmid, its lead investigational agent in Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC), following the completion of the pivotal cohort of the LEGEND trial.
'Amy brings a unique combination of P&L, full commercialization, gene therapy, deep analytics, and global experience to enGene,' said enGene CEO, Ron Cooper. 'We are thrilled to welcome Amy as our Chief Global Commercialization Officer and believe her leadership and track record of success will be a tremendous asset in preparing and executing the planned launch of detalimogene.'
Ms. Pott joins enGene from Astellas Pharma, where she most recently served as Senior Vice President (SVP), Strategic Brand Marketing, Ophthalmics and Rare Diseases, and previously as Head of Commercial, Gene Therapies. Prior to Astellas, she was President, North America for Swedish Orphan Biovitrum, and Global Vice President (GVP) U.S. Franchise Head for Internal Medicine and Oncology, as well as GVP, U.S. Commercial Operations at Shire. Before joining Shire, Ms. Pott was Vice President, Strategy, Planning and Analytics at Baxalta, Inc.
Ms. Pott holds a Master of Science in European Studies from the London School of Economics and a Bachelor of Arts in History from the University of Bristol.
'I am excited to join enGene at such a pivotal moment in its journey,' said Ms. Pott. 'I look forward to working with this talented team to advance the mission to help transform the treatment landscape for bladder cancer patients with our innovative genetic medicine.'
About Detalimogene
Detalimogene is a novel, investigational, non-viral genetic medicine for patients with high-risk, non-muscle invasive bladder cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-unresponsive disease. It is designed to be instilled in the bladder and elicit a powerful yet localized anti-tumor immune response.
Detalimogene was developed using the Company's Dually Derivatized Oligochitosan® (DDX) platform, a technology designed to transform how gene therapies are accessed by patients and utilized by clinicians. Medicines developed with the DDX platform can potentially overcome the limitations of viral-based gene therapies, simplify safe handling and cold storage complexities, and streamline both manufacturing processes and administration paradigms.
Detalimogene has received Fast Track designation from the U.S. Food and Drug Administration (FDA) based on its potential to address the high unmet medical need for patients with BCG-unresponsive carcinoma in situ (CIS) NMIBC with or without resected papillary tumors who are unable to undergo cystectomy. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
About enGene
enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene's lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 study, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene was developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.
To learn more, please visit enGene.com and follow us on LinkedIn, X and BlueSky.
Forward-Looking Statements
Certain statements contained in this press release may constitute 'forward-looking statements' within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and 'forward-looking information' within the meaning of Canadian securities laws (collectively, 'forward-looking statements'). enGene's forward-looking statements include, but are not limited to, statements regarding enGene's management teams' expectations, hopes, beliefs, intentions, goals, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words 'anticipate', 'appear', 'approximate', 'believe', 'continue', 'could', 'estimate', 'expect', 'foresee', 'intends', 'may', 'might', 'plan', 'possible', 'potential', 'predict', 'project', 'seek', 'should', 'would', and similar expressions (or the negative version of such words or expressions) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for example, statements about: our plans regarding the timing of our planned BLA submission to the Food and Drug Administration and our expectations as to the timing and anticipated results of the LEGEND study, the future growth of enGene, the potential benefits of detalimogene, and the potential benefits of medicines developed with the DDX platform.
Many factors, risks, uncertainties and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the Company's ability to recruit and retain qualified scientific and management personnel, establish clinical trial sites and enroll patients in its clinical trials, execute on the Company's clinical development plans and ability to secure regulatory approval on anticipated timelines, and other risks and uncertainties detailed in filings with Canadian securities regulators on SEDAR+ and with the U.S. Securities and Exchange Commission ('SEC') on EDGAR, including those described in the 'Risk Factors' section of the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 2024 (copies of which may be obtained at www.sedarplus.ca or www.sec.gov).
You should not place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. enGene anticipates that subsequent events and developments will cause enGene's assessments to change. While enGene may elect to update these forward-looking statements at some point in the future, enGene specifically disclaims any obligation to do so, unless required by applicable law. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
an hour ago
- Epoch Times
Wall Street Review: S&P 500 Breaks 6,000 in Broad Market Rally
The rally in U.S. stocks continued to broaden this week, driven by a resilient labor market and easing trade tensions between the United States and China. For the first time since it reached an all-time high in February, the S&P 500 Index retook the 6,000 mark on June 6 and closed up 1.5 percent for the week. The Dow Jones Industrial Average gained 1.17 percent to finish at 42,746. The Nasdaq rose by 2.18 percent to 19,529, while the Russell 2000 rallied 3.19 percent.
Yahoo
2 hours ago
- Yahoo
Is CoreWeave Stock a Buy Now?
New AI stock CoreWeave had its initial public offering in March 2025. High demand for AI computing power led to CoreWeave's first-quarter sales soaring more than 400% year over year. The company anticipates sustained revenue growth, but CoreWeave faces financial risks, including operating at a loss. 10 stocks we like better than CoreWeave › Investing in today's stock market can be tricky given the volatile macroeconomic climate, fueled by the Trump administration's ever-shifting tariff policies. But the artificial intelligence sector remains a robust investment opportunity as organizations around the world race to build artificial intelligence (AI) capabilities. Consequently, AI stocks provide the potential for great gains. One example is CoreWeave (NASDAQ: CRWV). The company went public in March at $40 per share. Since then, CoreWeave stock soared to a 52-week high of $166.63 in June. This hot stock remains more than triple its IPO price at the time of this writing. Can it go higher? Evaluating whether now is the time to grab CoreWeave shares requires digging into the company and unpacking its potential as a good investment for the long haul. CoreWeave delivers cloud computing infrastructure to businesses hungry for more computing capacity for their AI systems. The company operates over 30 data centers housing servers and other hardware used by customers to train their AI and develop inference, which is an AI's ability to apply what it learned in training to real-world situations. AI juggernauts such as Microsoft, IBM, and OpenAI, the owner of ChatGPT, are among its roster of customers. The insatiable appetite for AI computing power propelled CoreWeave's business. The company's first-quarter revenue rose a whopping 420% year over year to $981.6 million. Sales growth shows no sign of slowing down. CoreWeave expects Q2 revenue to reach about $1.1 billion. That would represent a strong year-over-year increase of nearly 170% from the prior year's $395 million. The company signs long-term, committed contracts, and as a result, it has visibility into its future revenue potential. At the end of Q1, CoreWeave had amassed a revenue backlog of $25.9 billion, up 63% year over year thanks to a deal with OpenAI. The company forecasts 2025 full-year revenue to come in between $4.9 billion and $5.1 billion, a substantial jump up from 2024's $1.9 billion. Although CoreWeave has enjoyed massive sales success, there are some potential pitfalls with the company. For starters, it isn't profitable. Its Q1 operating expenses totaled $1 billion compared to revenue of $981.6 million, resulting in an operating loss of $27.5 million. Even worse, its costs are accelerating faster than sales, which means the company is moving further away from reaching profitability. CoreWeave's $1 billion in operating expenses represented a 487% increase over the prior year, eclipsing its 420% year-over-year revenue growth. Another area of concern is the company's significant debt load. CoreWeave exited Q1 with $18.8 billion in total liabilities on its balance sheet, and $8.7 billion of that was debt. To keep up with customer demand for computing power, CoreWeave has to spend on expanding and upgrading AI-optimized hardware, and that's not cheap. As it adds customers, the company must expand its data centers to keep pace. Debt is one way it's funding these capital expenditures. Among the risks of buying its stock, CoreWeave admitted, "Our substantial indebtedness could materially adversely affect our financial condition" and that the company "may still incur substantially more indebtedness in the future." In fact, its Q1 debt total of $8.7 billion was a 10% increase from the prior quarter's $7.9 billion in debt. Seeing an increase in both expenses and debt is a concern, but because CoreWeave is a newly public company, there's not much history to know how well it can manage its finances over the long term. Q1 is the only quarter of financial results it's released since its initial public offering. If subsequent quarters reveal a trend toward getting costs and debt under control while continuing to show strong sales growth, CoreWeave stock may prove to be a worthwhile investment over the long run. But for now, only investors with a high risk tolerance should consider buying shares. Even then, another consideration is CoreWeave's stock valuation. This can be assessed by comparing its price-to-sales (P/S) ratio to other AI companies, such as its customer and fellow cloud provider Microsoft and AI leader Nvidia. CoreWeave's share price surged over recent weeks, causing its P/S multiple to skyrocket past that of Nvidia and Microsoft. The valuation suggests CoreWeave stock is overpriced at this time. Although CoreWeave's sales are strong, given its pricey stock and shaky financials, the ideal approach is to put CoreWeave on your watch list. See how it performs over the next few quarters, and wait for its high valuation to drop before considering an investment. Before you buy stock in CoreWeave, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CoreWeave wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Robert Izquierdo has positions in International Business Machines, Microsoft, and Nvidia. The Motley Fool has positions in and recommends International Business Machines, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Is CoreWeave Stock a Buy Now? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Better Fintech Stock: SoFi Technologies vs. Robinhood Markets
SoFi Technologies' earnings growth is accelerating as it benefits from its expanding slate of personal finance solutions. Shares of Robinhood Markets have hit a new all-time high thanks to its strong growth outlook and improved financial position. 10 stocks we like better than SoFi Technologies › Digital bank SoFi Technologies (NASDAQ: SOFI) and online brokerage Robinhood Markets (NASDAQ: HOOD) both leverage their innovative platforms to disrupt the traditional financial services sector. Their strong growth rates have translated into impressive returns: Shares of SoFi are up 95% in the past year, while Robinhood stock has climbed by a remarkable 246%. After such large gains, some investors may wonder if they can keep their rallies going. Let's consider which of these fintech leaders is a better buy for your portfolio today. SoFi Technologies has transformed from a student and personal loans specialist into a comprehensive financial services platform. Its digital-first, one-stop shop approach resonates with consumers. Today, it serves 10.9 million members, nearly twice as many as it served just two years ago. In the first quarter -- in what CEO Anthony Noto described as a "tremendous start to 2025" -- SoFi's adjusted net revenue surged 33% year over year while adjusted earnings per share (EPS) climbed 200% to $0.06. The bank's success reflects its ongoing diversification beyond lending products into more fee-based services, as its members are increasingly utilizing more of its banking accounts, credit cards, investing options, and other financial products. SoFi is now positioned for more consistently profitable growth and high-quality cash flows. Management expects the positive trends to continue: It's targeting full-year adjusted EPS of $0.27 to $0.28 -- nearly double the $0.15 result in 2024. This outlook highlights a key advantage of SoFi over Robinhood Markets, which faces greater earnings uncertainty, as its business is still tied to transaction volumes and shifting financial market conditions. Investors who are confident in SoFi's ability to execute its growth strategy and capture more market share from legacy banks have compelling reasons to buy and hold the stock for the long term. As robust as SoFi's operating and financial results have been, Robinhood's recent momentum has been even stronger. In the first quarter, net revenue increased 50% while EPS more than doubled to $0.37 from $0.17 in the prior-year period. The company that redefined retail investing with its pioneering commission-free trading model is capitalizing on its 25.8 million funded accounts, where users are trading more actively and directing more of their total assets to the platform. Much of the growth story stems from the cryptocurrency market boom. Crypto now represents 43% of the platform's total transaction volume and contributes 27% of total revenue. Still, Robinhood Markets is also diversifying its product and service offerings with professional-level trading tools, banking solutions, wealth management options, and the premium Robinhood Gold subscription, all of which are increasing the company's customer wallet share. Wall Street has cheered Robinhood's traction, sending the stock up 94% year-to-date to a high that surpassed the pandemic-era peak it set in 2021. Robinhood aims to replicate its U.S. success as it expands globally. It plans to launch service in the Asia Pacific region, and is bolstering its presence in the digital asset space through its recent acquisition of crypto exchange Bitstamp. Those international ambitions, compared to SoFi's more domestically focused operations, could support greater long-term top- and bottom-line growth, which would help justify the stock's premium valuation. Notably, both Robinhood and Sofi are trading at forward price-to-earnings (P/E) ratios near 50, suggesting the market's optimism about their potential is fairly equal. Investors who take the view that Robinhood is just getting started on its path toward a dominant position in the online brokerage space should consider making the stock a part of a diversified portfolio. Choosing which of these is the better fintech stock to buy now isn't easy. I'm bullish on both and predict each will deliver positive returns over the next year. If I were forced to pick just one to buy, though, I'd give the edge to SoFi Technologies, which appears to offer a compelling buy-the-dip opportunity with shares still down about 27% from their 52-week high. In my view, SoFi stands to benefit more from a resilient macroeconomic backdrop, fueling lending demand and earnings growth in the coming quarters, which would provide catalysts for the stock to rally higher. Meanwhile, Robinhood must contend with the lofty expectations baked into its stock price following its recent surge. The market's hopes for it could prove difficult to meet, potentially setting the stage for renewed stock price volatility ahead. Before you buy stock in SoFi Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and SoFi Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Better Fintech Stock: SoFi Technologies vs. Robinhood Markets was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
